• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

148.34 +10.77 (+7.83%)
Official Closing Price Updated: 4:10 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
July 14, 2021
Gainers Qualigen Therapeutics (NASDAQ:QLGN) stock moved upwards by 8.98% to $1.94 during Wednesday's pre-market session. The market value of their outstanding shares... 
Via Benzinga
News headline image
William Blair Downgrades Glaukos After Disappointing CMS Rate; Shares Drop ↗
July 14, 2021
Centers for Medicare and Medicaid Services (CMS) issued its fiscal 2022 proposed physician fee schedule, which included two combined Category I cataract plus stent procedure... 
Via Benzinga
News headline image
Glaukos Comments on the Centers for Medicare and Medicaid Services 2022 Proposed Physician Fee Schedule
July 14, 2021
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Stock Sees Its Relative Strength Rating Improve To Key Above-80 Level ↗
July 01, 2021
Glaukos stock had its Relative Strength (RS) Rating upgraded from 78 to 81 Thursday. Is Glaukos on your watchlist? 
Via Investor's Business Daily
News headline image
Glaukos's Earnings: A Preview ↗
May 04, 2021
Glaukos (NYSE:GKOS) announces its next round of earnings this Wednesday, May 05. Here is Benzinga's look at Glaukos's Q1 earnings report. Net Income, Earnings, And Earnings Per... 
Via Benzinga
News headline image
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗
May 01, 2021
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Why Glaukos's Stock is Up During Today's Session ↗
April 08, 2021
Glaukos's Stock Price And Volume Action Glaukos (NYSE:GKOS) is curre... 
Via Benzinga
News headline image
Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in U.S. NDA Phase 3 Clinical Trials for iDose® TR
June 10, 2021
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Australia’s TGA Regulatory Approval for PRESERFLO™ MicroShunt
June 08, 2021
From Glaukos
Via Business Wire
News headline image
Glaukos Announces Participation in the William Blair 41st Annual Growth Stock Conference
May 19, 2021
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Expands its PRESERFLO™ MicroShunt Relationship with Santen via New License Agreement
May 18, 2021
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Corp (GKOS) Q1 2021 Earnings Call Transcript ↗
May 05, 2021
GKOS earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Glaukos Corporation Announces First Quarter 2021 Financial Results
May 05, 2021
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces the Release of its 2020 Sustainability Report
April 27, 2021
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Global Licensing Agreement Amendment with Intratus, Inc. to Include the Treatment of Presbyopia
April 22, 2021
From Glaukos Corporation
Via Business Wire
News headline image
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues ↗
May 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs ↗
April 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) Alexion Pharmaceuticals,... 
Via Benzinga
News headline image
Glaukos Corporation to Release First Quarter 2021 Financial Results after Market Close on May 5
April 14, 2021
From Glaukos Corporation
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 8, 2021 ↗
April 08, 2021
Upgrades According to Oppenheimer, the prior rating for Glaukos Corp (NYSE:GKOS) was changed from Perform to Outperform. Glaukos earned $0.02 in the fourth quarter,... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap